METHODS: Retrospective multicentre study of all patients with Tubiana stage 3-4 Dupuytren contracture treated with percutaneous needle aponeurotomy, with no ultrasound assistance, from 2012 to 2022. Patient demographics, disease severity, treatment-related complications, and the incidence of recurrence were identified. An overview of therapeutic treatment options has accounted for 52 relevant sources spanning the 2007-2023 time period.
RESULTS: Overall, 41.7% (N = 200) of patients were females, the mean age was 72 years (60-89), the right hand was treated in 54.2% (N = 260) of patients. The little finger was involved in 50% of the patients. The 12 months mean PED was 9°, the mean quickDASH was 8, the mean URAM 6. Minor complications were reported in 18.7% (N = 90) of patients, typically skin lacerations (83.3%) with no clinical sequelae, and no major complications were reported. Recurrence occurred in 30% (N = 144) of patients.
CONCLUSIONS: Percutaneous needle fasciotomy is safe and reliable even in patients with advanced Dupuytren disease, resulting in predictably acceptable outcome with low risk of complications.
方法:对所有Tubiana3-4期Dupuyten挛缩症患者进行回顾性多中心研究,没有超声波辅助,从2012年到2022年。患者人口统计学,疾病严重程度,治疗相关并发症,并确定了复发的发生率。在2007-2023年期间,治疗性治疗方案的概述占52个相关来源。
结果:总体而言,41.7%(N=200)的患者是女性,平均年龄为72岁(60-89岁),54.2%(N=260)的患者接受了右手治疗.50%的患者受累于小手指。12个月平均PED为9°,平均quickDASH为8,平均URAM为6。18.7%(N=90)的患者报告了轻微的并发症,典型的皮肤撕裂(83.3%),没有临床后遗症,无重大并发症报告.30%(N=144)的患者复发。
结论:经皮穿刺筋膜切开术即使在晚期Dupuytren病患者中也是安全可靠的,导致可预测的可接受的结果和低的并发症风险。